OraSure Technologies (NASDAQ:OSUR - Get Free Report) is anticipated to post its quarterly earnings results after the market closes on Tuesday, February 25th. Analysts expect OraSure Technologies to post earnings of ($0.05) per share and revenue of $36.76 million for the quarter. Investors that are interested in registering for the company's conference call can do so using this link.
OraSure Technologies Price Performance
Shares of NASDAQ OSUR traded down $0.08 during mid-day trading on Friday, reaching $3.80. 1,284,007 shares of the company's stock were exchanged, compared to its average volume of 817,897. The firm has a market capitalization of $283.44 million, a price-to-earnings ratio of 25.33 and a beta of 0.05. The firm has a 50-day moving average price of $3.81 and a two-hundred day moving average price of $4.03. OraSure Technologies has a 52 week low of $3.52 and a 52 week high of $8.04.
Wall Street Analyst Weigh In
Separately, StockNews.com cut shares of OraSure Technologies from a "buy" rating to a "hold" rating in a research note on Thursday, February 13th.
Read Our Latest Stock Analysis on OSUR
OraSure Technologies Company Profile
(
Get Free Report)
OraSure Technologies, Inc, together with its subsidiaries, provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally. The company's products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D.
See Also
Before you consider OraSure Technologies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and OraSure Technologies wasn't on the list.
While OraSure Technologies currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
